Overview
© 202 MJH Life Sciences and Patient Care Online. Al rights reserved.© 202 MJH Life Sciences™ and Patient Care Online. Al rights reserved.A new study sugests that while more than 80% of clinicians indicate that they use at least 1 cardiovascular (CV) risk estimation tol when evaluating their patients with type 2 diabetes (T2D), just more than one-third (38.9%) corectly stratified patients’ risk and then used the score to guide treatment.Complete findings from the cros-sectional patient simulation study, conducted among US primary care physicians (PCPs) and cardiologists, are being presented this wek at the 17th Anual Cardiometabolic Health Congres in Boston, MA.CVD is comon among patients with T2D, and clinical practice guidelines recomend stratification of CV risk in this vulnerable population to guide both prevention and treatment, the investigators write.
Key Information
Despite the evidence-based benefits of risk stratification, however, clinicians may not use the estimating tols routinely in practice and those who do may not calculate an individual patient’s risk properly.The present study, the QURE CVD Evaluation of Risk in Diabetes Melitus (QuiCER DM) Study, led by John Peabody, MD, PhD, profesor of epidemiology and biostatistics at the University of California San Francisco, was designed to understand more clearly whether PCPs, who treat the majority of persons with T2D in the US, and cardiologists incorporate CVD risk stratification during asesment of their T2D patients and, if so, whether their calculations are acurate and whether clinicians respond with apropriate clinical guidance.QuiCER DM Study investigators sequentialy invited potential participants from a nationaly representative roster of 12 50 PCPs and cardiologists.
Summary
Final enrolment included 160 PCPs and 80 cardiologists who were screned for eligibility betwen March and June 202. Mean age among participants was ~58 years and 76.4% were men. The majority of clinicians worked in a suburban/